Hemophilia Drug Can Damage Heart, Study Finds

Wednesday, 03 Nov 2010 07:36 PM


  Comment  |
   Contact Us  |
|  A   A  
  Copy Shortlink

* Doctors give NovoSeven to stop other serious bleeding

* 35 studies weighed in new analysis

* Danger most pronounced in older patients

By Gene Emery

BOSTON (Reuters) - Using high doses of Novo Nordisk's anti-clotting medicine to treat dangerous bleeding in non-hemophiliacs may raise the risk of heart attack or related complications, researchers said Wednesday.

The drug, NovoSeven, is a genetically engineered version of factor VII, a key protein missing in some people with the bleeding disease hemophilia.

Some doctors prescribe the drug in "off-label" use to stop unwanted bleeding associated with stroke, trauma, surgery, transplantation and other medical conditions. Doctors may prescribe any approved drug for any reason they want to.

But this drug may not be worth the risk, said Dr. Marcel Levi of the University of Amsterdam and colleagues at Novo Nordisk.

Their analysis of 35 studies found that the overall likelihood that an artery would clog was 68 percent higher with NovoSeven therapy compared to a placebo.

The risk of heart attack, angina or related complication more than doubled, the researchers reported in the New England Journal of Medicine .

People over 65 who got the drug were more than twice as likely to develop an unwanted clot in an artery than younger patients, they found. Those over 74 were three times more likely.

"This is a highly effective drug in patients with excessive blood loss in various circumstances. But the main message is you need to realize that there is a price to be paid," Levi said in a telephone interview.

"If a patient's bleeding so serious he or she may have a major problem or even die, you can accept the small increased risk of having an arterial thrombosis (clot)," Levi said.

"On the other hand, if it's not excessive bleeding and there are other options to explore, the safety issue may hold you back from doing this."

The treatment did not increase the risk of unwanted clots in veins, regardless of age, the researchers found. It increased the risk of stroke, but not enough to be statistically significant.

Dr. Louis Aledort of the Mount Sinai School of Medicine in New York said in a commentary that 4 percent of the NovoSeven used at his hospital is for non-approved therapy. "At other centers, the rate of off-label use may be even higher," Aledort said.

Levi said hospitals that are quick to give the drug may now want to reconsider that practice. (Editing by Philip Barbara)

© 2014 Thomson/Reuters. All rights reserved.

  Comment  |
   Contact Us  |
  Copy Shortlink
Around the Web
Join the Newsmax Community
Please review Community Guidelines before posting a comment.
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
Zip Code:
Privacy: We never share your email.
Hot Topics
Follow Newsmax
Like us
on Facebook
Follow us
on Twitter
Add us
on Google Plus
Around the Web
Top Stories
You May Also Like

Judge Orders Extra Voting Help for Alaska Natives

Monday, 22 Sep 2014 20:37 PM

A federal judge on Monday ordered the state to take additional steps to provide voting materials to Alaska Native voters . . .

Pew Poll: Nearly Half of Americans Want More Religion in Politics

Monday, 22 Sep 2014 19:55 PM

Almost half of Americans think religion and politics should mix, according to a new survey.
 . . .

GAO: Feds' Consumer Watchdog Not Protecting Credit Data

Monday, 22 Sep 2014 19:45 PM

The agency created by President Barack Obama to protect consumers from financial fraud has amassed sensitive credit-card . . .

Most Commented

Newsmax, Moneynews, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, NewsmaxWorld, NewsmaxHealth, are trademarks of Newsmax Media, Inc.

America's News Page
©  Newsmax Media, Inc.
All Rights Reserved